Rakesh Dixit, PhD, President & CEO, Bionavigen
Bispecific antibodies incorporating various anticancer modalities, including drug conjugates, enhanced CD3- and TCR-based BiTEs are revolutionizing the war on deadly solid and heme cancers. However, challenges remain in development of bispecific biologics. The presentation will discuss the top ten challenges, including challenges to selection of target pairs and effector function, efficacy of safety of CD3-based biologic, case studies of novel bispecific platforms of PD-1:CTLA4 bispecific and Her2-biparatopic, and bispecific ADCs. Additionally, manufacturing, clinical and regulatory challenges will be discussed.